A Study of Controlled Lactulose Withdrawal

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

7 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-09-30

Study Completion Date

2012-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

After resolution of the initial episode of hepatic encephalopathy (HE), lactulose is routinely continued indefinitely as maintenance therapy. Although widely used for this indication, lactulose has never been shown in randomized, controlled trials to be effective for preventing exacerbations of HE. Indeed, lactulose was found to be ineffective at preventing HE when administered prophylactically to patients undergoing portosystemic shunt insertion. While some patients may be lactulose dependent following an initial episode of HE, it is likely that most could have their lactulose discontinued with no adverse consequences.

This goal is worth pursuing because lactulose is not innocuous. It has an unpleasant taste, and it routinely produces gastrointestinal symptoms, including bloating, gas and diarrhea. In high doses it can cause incontinence, dehydration and electrolyte derangements. Patients universally dislike taking lactulose and often are noncompliant with treatment. A recent trial showed that patients on lactulose had a substantial risk of hospital admissions due to lactulose-related complications and treatment non-compliance.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Lactulose in Children With Chronic Liver Disease

NCT00811434

Minimal Hepatic Encephalopathy

TERMINATED PHASE2

PEG (Polyethylene Glycol)Versus Lactulose For Treatment Of Overt Hepatic Encephalopathy

NCT03100513

Hepatic Encephalopathy

UNKNOWN PHASE4

Rifaximin Plus Lactulose Versus Lactulose Alone for the Treatment of Hepatic Encephalopathy: a Double Blind Randomized Trial

NCT01218568

Hepatic Encephalopathy

COMPLETED NA

Phase II Study of Lactulose and Circadian Rhythms in Patients With Cirrhosis

NCT00004796

Cirrhosis Hepatic Encephalopathy Portal Hypertension

COMPLETED PHASE2

Intravenous Branched Chain Amino Acids for Hepatic Encephalopathy in ACLF

NCT04238416

Hepatic Encephalopathy Acute-On-Chronic Liver Failure

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In this pilot study we propose to perform controlled lactulose withdrawal in selected patients with HE whose initial presentation follows a clearly defined, reversible precipitating event or those with stable, chronic HE. We hypothesize that a majority of these patients can be withdrawn from daily lactulose therapy without deterioration of cognitive function, and that lactulose withdrawal will improve symptoms and quality of life for these individuals. We propose to carry out a comprehensive battery of clinical, laboratory, microbiological and psychometric evaluations before and after lactulose withdrawal. We will closely follow changes in cognitive function and re-institute lactulose therapy at the first sign of clinical deterioration. Through multivariate analysis we propose to develop a model to discriminate between treatment dependent and treatment independent patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatic Encephalopathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lactulose withdrawal

Patients who were started on lactulose as a result of a precipitated HE episode underwent analysis while they were on lactulose; after this they underwent a controlled lactulose withdrawal with 3 visits post-withdrawal at 2 days, 14 days and 30 days after lactulose withdrawal

Group Type EXPERIMENTAL

lactulose

Intervention Type DRUG

withdrawal of lactulose

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

lactulose

withdrawal of lactulose

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of hepatic cirrhosis based on biopsy, clinical and/or radiological findings.
* Stable HE (chronic): On daily lactulose for more than 6 months without hospitalization for HE within 3 months of enrollment.
* Treated with lactulose on a daily basis, with restoration of mental status to baseline.
* Lives with an adult individual who is willing to serve as a full-time caregiver.
* Able and willing to give informed consent.

Exclusion Criteria

* Use of antibiotics, including rifaximin.
* Patient without an adult caregiver.
* Pre-existing focal neurological deficits, seizures or other indication of structural neurological disorder.
* Actively abusing illicit drugs or alcohol.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No